A Phase 3 interventional study of Atezolizumab and Biospecimen Collection in Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 and Stage II Lung Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Active, not recruiting at 390 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 27 under way, 5 of them phase 3. atezolizumab · Carcinoma, Non-Small-Cell Lung.
Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment, is one of 9 that started in 2020, is one of 18 in phase 3, reaches primary completion later than 1 of the 26 other live ones, and was the 50th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 6 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
EuroCityClinic LLC · Sites in Russia
Ages 18+
Fundación GECP · Sites in Spain
Ages 18+
By country, each count listing its studies:
atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, atezolizumab is the treatment under test here. Read study by study →
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 52 · Phase 3 19 · Phase 4 3
First in 2013; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 417 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 81 interventional studies. Of the 47 that completed or were terminated, 30 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 81 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
176 studies in Carcinoma, Non-Small-Cell Lung by National Cancer Institute (NCI): 14 open now, 36 under way, 9 of them phase 3. Of 132 finished, 55 (42%) have results posted.
Among the 176 studies in Carcinoma, Non-Small-Cell Lung by National Cancer Institute (NCI), this one is the 17th largest by enrollment of the 154 interventional ones that give a count, is one of 6 that started in 2020, is one of 20 in phase 3, reaches primary completion later than 6 of the 34 other live ones, and was the 157th registered.
National Cancer Institute (NCI)’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1993.
10 of the studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT04302025Genentech, Inc.A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | 2026-11-30 |
| NCT03786692Fox Chase Cancer CenterPhase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | 2026-12 |
| NCT04691817Abramson Cancer Center at Penn MedicineTocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | 2026-12 |
| NCT05340309University of Southern CaliforniaSubcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among National Cancer Institute (NCI)’s 176 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.
SECONDARY OBJECTIVES:
I. To compare investigator-assessed progression-free survival (IA-PFS) between the arms.
II. To compare progression free survival (PFS) by blinded independent centralized review (BIRC) between the arms in a random subset of patients.
III. To evaluate distant, locoregional, and local failure rates within each treatment arm.
IV. To evaluate the frequency and severity of toxicities within each treatment arm.
ADDITIONAL OBJECTIVE:
I. To collect specimens for banking.
HEALTH-RELATED QUALITY OF LIFE (HRQOL) OBJECTIVE:
I. This objective will not be met, as the study was closed following the first interim analysis.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 1 cycle 3, patients also undergo SBRT for 3-8 treatments every 2 days or once daily (QD) over 1-3 weeks. Patients undergo fludeoxyglucose F-18 (FDG)-positron emission tomography/computed tomography (PET/CT) during screening. Patients undergo blood sample collection and CT scans throughout the trial.
ARM B: Beginning 21 days after randomization, patients undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
After completion of study treatment, patients are followed for 5 years after randomization.
Inclusion Criteria:
Disease must have one or more of the following high-risk features:
Patient must not have known (LVEF) \< 40% within 28 days prior to randomization
Patient must be tested for within 28 days prior to randomization. Patient must not have active (chronic or acute) hepatitis B virus (HBV) infection. Patients may have past or resolved HBV infection
Patient must be tested for within 28 days prior to randomization. Patient must not have active hepatitis C virus (HCV) infection
Patients must not have received a live, attenuated vaccine within 28 days prior to randomization
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 1 cycle 3, patients also undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
Drug: Atezolizumab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation Therapy
Beginning 21 days after randomization, patients undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation Therapy
Given IV
Also known as: MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo CT or PET/CT
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Undergo FDG PET/CT
Also known as: 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18
Undergo PET/CT
Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
Ancillary studies
Also known as: Quality of Life Assessment
Ancillary studies
Undergo SBRT
Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Overall Survival
Count of participants who have died, measured at two years from trial registration.
Time frame: From date of registration up to two years
Incidence of Adverse Events
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Time frame: Up to 5 years after registration
IA-PFS
Compare investigator-assessed progression-free survival (IA-PFS) between the arms. IA-PFS is defined as 20% increase in the longest diameter of the primary lung tumor over smallest measurement observed using the same techniques as baseline, as well as an absolute increase of at least 0.5 cm, accompanied by confirmatory study (unequivocal PET findings or biopsy) OR appearance of any new lesion/site OR death due to disease without prior documentation of progression OR unequivocal PET findings and/or biopsy confirming malignancy in the absence of growth.
Time frame: From registration up to 5 years
Progression Free Survival
Compare PFS (progression free survival) by blinded independent centralized review (BIRC) between the arms in a random subset of patients. PFS is defined as time from date of randomization to date of first documentation of progression assessed by BICR, or death due to any cause. PFS-BICR-1 for patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) will be used as the date of progression.
Time frame: Up to 5 years from registration
Distant, Locoregional, Local Failure Rates.
Evaluate distant, locoregional, and local failure rates within each treatment arm. Treatment failure is defined as time from date of randomization to date of first documentation of investigator-assessed progression or symptomatic deterioration (as defined above), early discontinuation of treatment, or death due to any cause. Time to treatment failure for patients last known not to have failed treatment are censored at the date of last contact.
Time frame: Up to 5 years from registration
414 participants were enrolled and 400 met eligibility requirements at the time of interim analysis dataset curation. 3 participants were enrolled after interim analysis (primary closure date) dataset curation and are not included in this participants flow.
| Milestone | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Started | 210 | 207 |
| Completed | 85 | 167 |
| Not completed | 125 | 40 |
| Withdrew: On treatment | 46 | 16 |
| Withdrew: Ineligible | 8 | 6 |
| Withdrew: Adverse event | 16 | 1 |
| Withdrew: Withdrawal by subject | 8 | 5 |
| Withdrew: Progression | 7 | 0 |
| Withdrew: Under review | 32 | 11 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other - not protocol specified | 5 | 0 |
| Withdrew: Enrolled after interim analysis data was curated | 2 | 1 |
Count of participants who have died, measured at two years from trial registration.
| participants | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Overall Survival | 19 | 14 |
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Results for this outcome have not been posted.
Compare investigator-assessed progression-free survival (IA-PFS) between the arms. IA-PFS is defined as 20% increase in the longest diameter of the primary lung tumor over smallest measurement observed using the same techniques as baseline, as well as an absolute increase of at least 0.5 cm, accompanied by confirmatory study (unequivocal PET findings or biopsy) OR appearance of any new lesion/site OR death due to disease without prior documentation of progression OR unequivocal PET findings and/or biopsy confirming malignancy in the absence of growth.
Results for this outcome have not been posted.
Compare PFS (progression free survival) by blinded independent centralized review (BIRC) between the arms in a random subset of patients. PFS is defined as time from date of randomization to date of first documentation of progression assessed by BICR, or death due to any cause. PFS-BICR-1 for patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) will be used as the date of progression.
Results for this outcome have not been posted.
Evaluate distant, locoregional, and local failure rates within each treatment arm. Treatment failure is defined as time from date of randomization to date of first documentation of investigator-assessed progression or symptomatic deterioration (as defined above), early discontinuation of treatment, or death due to any cause. Time to treatment failure for patients last known not to have failed treatment are censored at the date of last contact.
Results for this outcome have not been posted.
Reported as the count of participants who have died, measured at two years.
| participants | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Overall Survival for White Participants | 14 | 13 |
Reported as the count of participants who have died, measured at two years.
| participants | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Overall Survival in Non White Participants | 5 | 1 |
Reported as the count of participants who have died, measured at two years.
| participants | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Overall Survival in Male Participants | 9 | 6 |
Reported as the count of participants who have died, measured at two years.
| participants | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Overall Survival in Female Participants | 10 | 8 |
Reported as the count of participants who have died, measured at two years.
| participants | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Overall Survival in Non Hispanic Participants | 19 | 14 |
Reported as the count of participants who have died, measured at two years.
| participants | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| Overall Survival in Hispanic Participants | 0 | 0 |
Collected over Up to 5 years after registration. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Atezolizumab, SBRT) | 49/200 (24.5%) | 42/193 (21.8%) | 188/193 (97.4%) |
| Arm B (SBRT) | 50/200 (25%) | 0/194 (0%) | 86/194 (44.3%) |
| Event | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| HypoxiaRespiratory, thoracic and mediastinal disorders | 11/193 | 0/194 |
| Lung infectionInfections and infestations | 10/193 | 0/194 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 6/193 | 0/194 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/193 | 0/194 |
| DiarrheaGastrointestinal disorders | 3/193 | 0/194 |
| Acute kidney injuryRenal and urinary disorders | 3/193 | 0/194 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/193 | 0/194 |
| HypertensionVascular disorders | 3/193 | 0/194 |
| AnemiaBlood and lymphatic system disorders | 2/193 | 0/194 |
| Myocardial infarctionCardiac disorders | 2/193 | 0/194 |
| Event | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) |
|---|---|---|
| FatigueGeneral disorders | 97/193 | 61/194 |
| HyperglycemiaMetabolism and nutrition disorders | 61/193 | 1/194 |
| AnemiaBlood and lymphatic system disorders | 50/193 | 3/194 |
| DiarrheaGastrointestinal disorders | 50/193 | 2/194 |
| CoughRespiratory, thoracic and mediastinal disorders | 49/193 | 18/194 |
| Lymphocyte count decreasedInvestigations | 47/193 | 3/194 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 43/193 | 17/194 |
| ConstipationGastrointestinal disorders | 36/193 | 1/194 |
| HypoalbuminemiaMetabolism and nutrition disorders | 36/193 | 0/194 |
| NauseaGastrointestinal disorders | 35/193 | 10/194 |
| Age, Continuous(years) | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) | Total |
|---|---|---|---|
| Median | 72.1 (40.5 to 88.9) | 73.5 (52 to 91.2) | 72.6 (40.5 to 91.2) |
| Sex: Female, Male(Participants) | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) | Total |
|---|---|---|---|
| Female | 99 | 117 | 216 |
| Male | 101 | 83 | 184 |
| Race/Ethnicity, Customized(Participants) | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) | Total |
|---|---|---|---|
| White | 168 | 161 | 329 |
| Black | 18 | 27 | 45 |
| Asian | 4 | 6 | 10 |
| Native American | 2 | 2 | 4 |
| Multi-racial | 1 | 2 | 3 |
| Unknown | 7 | 2 | 9 |
| Tumor Size(Participants) | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) | Total |
|---|---|---|---|
| <4cm | 172 | 171 | 343 |
| >=4cm | 28 | 29 | 57 |
| Tumor Location(Participants) | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) | Total |
|---|---|---|---|
| Central | 63 | 64 | 127 |
| Peripheral | 137 | 136 | 273 |
| ECOG PS(Participants) | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) | Total |
|---|---|---|---|
| 0-1 | 177 | 179 | 356 |
| 2 | 23 | 21 | 44 |
| Hispanic(Participants) | Arm A (Atezolizumab, SBRT) | Arm B (SBRT) | Total |
|---|---|---|---|
| Yes | 8 | 5 | 13 |
| No | 186 | 189 | 375 |
| Unknown | 6 | 6 | 12 |
Showing the first 100 of 390 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Data sharing details ↗ · grants.nih.gov
Ran from Aug 2020 to primary completion in Aug 2024, 48 months.
Results were first posted in Oct 2026, 2 years 1 month after primary completion.
Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's 48 months is below that.
Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atezolizumab
Carcinoma, Non-Small-Cell Lung →
National Cancer Institute (NCI) →